Refractory Systemic Lupus Erythematous (SLE): Identification and pharmacological management

Webinar for healthcare professionals. Disease-specific.

Short description
The webinar is focused on the identification and pharmacological management of Refractory Systemic lupus erythematosus (SLE). SLE is characterized by an aberrant immune response, leading to an extremely heterogeneous clinical presentation, potentially affecting different systems and organs. Despite the fact that SLE mortality has greatly decreased since the introduction of steroids, some forms of refractory/severe SLE still have the potential to result in permanent organ damage as well as increased mortality and morbidity. Furthermore, SLE patients with multiple comorbidities may face a clinical conundrum and have a bad prognosis. An improved prognosis for severe refractory SLE depends on prompt and appropriate treatment. Due to the scarcity of solid data from a well-characterized group of patients with refractory/severe SLE coming from randomized controlled studies, this webinar aims to shed light on this with real-world data and available evidence.

Prof. Dario ROCCATELLO
Prof. Roccatello major research interests include the management of patients with autoimmune conditions, with a specific focus on Systemic Lupus Erythematosus, vasculitis and cryoglobulinemia.
He is Full Professor in Nephrology and head of the University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERN-Reconnect, ERK-net, and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital ASL Città di Torino and University of Torino.
He is the author or co-author of over 430 scientific publications. His recent study on topic related to this webinar, “Daratumumab monotherapy for refractory lupus nephritis.” was recently published in Nature Medicine.

Moderator: Prof. Savino Sciascia